National File Coronavirus vaccine maker Moderna Therapeutics issued an initial public offering (IPO) for its stock in 2018 that made now-disputed statements in an attempt to portray messenger RNA (mRNA) as an “impermanent” ingredient that does not change “genes or cell DNA.” But research has found that mRNA, which is a main ingredient in Moderna and also Pfizer-BioNTech Coronavirus injections, permanently affects and alters the human body.
Moderna’s IPO spoke of “transformative medicines based on messenger RNA.” The Moderna IPO in 2018 was reported at the time to be the biggest initial public offering in the history of the biotech sector, with underwriters represented by Morgan Stanley, Goldman Sachs, Barclays Capital, JP Morgan and other major financial firms…
